09.07.2019 • News

Archroma Buys BASF’s Brightening Agents

Archroma Buys BASF’s Brightening Agents (c) BASF
Archroma Buys BASF’s Brightening Agents (c) BASF

Swiss dyes and specialty chemicals company Archroma has agreed to buy BASF’s stilbene-based optical brightening agents (OBA) business for paper and powder detergent applications. Financial terms were not disclosed.

The agreement was signed between Archroma India and BASF India and includes a manufacturing plant in Ankleshwar, India, where around 100 people are currently employed. Completion is anticipated in the fourth quarter of 2019.

“This acquisition will not only allow Archroma to strengthen our OBA supply to customers in the packaging & paper industry, in particular in India and Asia, it will also help us develop our portfolio offering to customers in the detergents market with high-performance powder OBA,” said Marcos Furrer, Archroma’s president of packaging & paper specialties.

BASF said the divestment was in line with its strategy of “actively managing” its portfolio.

Archroma bought another BASF business in 2015, that time it was BASF’s textile chemicals assets, which included the legal entity BASF Pakistan based in Karachi.

The Reinach-based company has been owned by private equity group SK Capital Partners since 2013.

Company

Logo:

Archroma


Pratteln
Switzerland

Company contact







Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read